Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

BI-6727 shows promise in phase I/II trial in acute myeloid leukemia

Dec. 9, 2010

Phase I/II data presented on MLN-8237 in hematological malignancies

Dec. 9, 2010

Phase II results for plitidepsin in peripheral T-cell lymphoma presented

Dec. 7, 2010

Activity seen with ARRY-520 in patients with relapsed/refractory multiple myeloma

Dec. 7, 2010

ACT Biotech describes activity of Aurora kinase inhibitor ACTB-1010

Dec. 7, 2010

Oncolytic prodrug BMS-817378 selected for clinical development

Dec. 7, 2010

Interim data from phase I trial of PF-03732010 in advanced solid tumors reveal good tolerability

Dec. 7, 2010

Preliminary efficacy reported in first-in-human trial of LFB-R603 in chronic lymphocytic leukemia

Dec. 7, 2010

TAvi6, a bispecific antibody targeting VEGF-A/ANG-2 inhibits angiogenesis in vivo

Dec. 3, 2010

Gradient Echo Plural Contrast Imaging monitors progression of MS

Dec. 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...